Sarcopenia Treatment Market is expected to reach US$ 5,264.76 million by 2030

Pharmacies Segment to Hold Significant Share of Sarcopenia Treatment Market During 2022–2030  

According to our latest study on "Sarcopenia Treatment Market Forecast to 2030 – Global Analysis – Treatment Type, and Distribution Channel," the sarcopenia treatment market value is expected to reach US$ 5,264.76 million by 2030 from US$ 3,397.62 million in 2022. The report explains key factors driving the market and mentions prominent players with their developments. An upsurge in the geriatric population and a rise in malnutrition and vitamin deficiency among adults are the key factors driving the market growth. However, the unavailability of direct interventions hampers the sarcopenia treatment market progress.

Sarcopenia is a geriatric condition caused by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050. According to the National Library of Medicine, China's elderly population is expanding at one of the quickest rates in the world. By 2040, 28% of China's population is expected to be over 60 years of age. As per national figures of Japan, 29.1% of the 125 million people living in the country are aged 65 or older. According to the 2020 Census, the US population aged 65 and above increased about five times faster than the total population during 1920–2020. In 2020, the number of older population reached 55.8 million, or 16.8% of the total population of the US. The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Supplements are sold at pharmacies as over-the-counter (OTC) medicines. Many OTC products composed of various dietary supplements such as Vitamin D, Vitamin B12, and protein supplements are available on the market, which are prescribed as a part of the treatment for sarcopenia.

Sarcopenia Treatment Market, by Treatment Type:

The sarcopenia treatment market, by treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The vitamin D and calcium supplements segment held the largest share of the market in 2022. It is anticipated to record the highest CAGR of 6.5% during 2022–2030. Being a fat-soluble vitamin, vitamin D is crucial for maintaining calcium homeostasis and healthy bone metabolism. The supplementation of vitamin D has been studied as a useful dietary strategy to reduce the risk of sarcopenia. Older adults with low vitamin D levels are more susceptible to sarcopenia, often associated with falls, hospitalization, and other adverse effects.

Abbott Laboratories, Bayer AG, Metagenics LLC, Nestle Health Science SA, Novartis AG, Pfizer Inc., Sanofi SA, Amway Corp, GSK Plc, and Makers Nutrition LLC are among the prominent sarcopenia treatment market players.

The report segments the sarcopenia treatment market as follows:

The sarcopenia treatment market has been segmented on the basis of treatment type and distribution channel. The market, by treatment type, is segmented into vitamin D and calcium supplements, protein supplements, vitamin B12 supplements, and others. The sarcopenia treatment market, based on distribution channel, is segmented into pharmacies, retail channels, online channels, and others. The market, based on geography, is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, Italy, UK, Spain, and Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and Rest of Asia Pacific), Middle East & Africa (Saudi Arabia, UAE, South Africa, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com